Jacqueline T. Bork, MD, MS

2000 – 2004  B.A., Biochemistry, New York University (Cum Laude)

2004 – 2008  M.D., SUNY Downstate College of Medicine

2017 – 2020  M.S., Clinical Research, University of Maryland Baltimore Graduate School

2008 – 2009  Internship, Mount Sinai School of Medicine

2009 – 2011  Residency, Internal Medicine, Mount Sinai School of Medicine

2012 – 2014  Fellowship, Infectious Diseases, University of Maryland School of Medicine

Dr. Bork is an Infectious Disease physician with primary interests in antimicrobial stewardship and infections in the immunocompromised host.  She attended New York University where she majored in Biochemistry and went on to SUNY Downstate College of Medicine to complete her medical training.  She completed her Internal Medicine residency training at the Mount Sinai Medical Center in New York and her Infectious Diseases fellowship training at the University of Maryland Medical Center in Baltimore. She also went on to complete a Master of Clinical Research at the University of Maryland Graduate School in Baltimore.

Dr. Bork has prominent leadership roles in the Antimicrobial Stewardship Programs at the VA Maryland Health Care System and University of Maryland Medical Center.  Since 2016, Dr. Bork has developed a multidisciplinary and comprehensive antimicrobial stewardship program at the local VA to include acute care, long term care and outpatient areas.  In 2021, Dr. Bork was appointed Medical Director of the Antimicrobial Stewardship Program at the University of Maryland Medical Center. 

Cancer and transplant patients are at high risk for both infections and complications of antibiotics (e.g., C. difficile infection, antimicrobial resistance, toxicity).  Balancing these opposing factors is a challenge but lends itself to the opportunity to improve antimicrobial stewardship practices in this vulnerable patient population, an intersection that Dr. Bork is passionate about.

Dr. Bork’s scholarly work includes: (1) Identifying impactful interventions and strategies to optimize antimicrobial selection, (2) Understanding the role of infectious disease consultation versus antimicrobial stewardship in managing infections in hospitalized patients, (3) Discovering ways to improve efficiency and effectiveness in antimicrobial practice, and (4) Leveraging advancing diagnostics to improve the accuracy of antibiotics in hospitalized patients.

Antimicrobial Stewardship, Immunocompromised Host

Bork JT, Leekha S, Heil E, LiCheng Z, Badamas R, Johnson JK. Rapid Testing using Verigene Microarray in Combination with Antimicrobial Stewardship Intervention in Gram-negative Bacteremia Antimicrob Agents Chemother. 2015 Mar; 59(3):1588-95.

Heil E, Bork JT, Schmalzle SA, Kleinberg M, Kewalramani A, Gilliam BL, Buchwald UK. Implementation of an Infectious Disease Fellow Managed Pencillin Allergy Skin Testing Service. Open Forum Infect Dis. 2016 3(3):ofw155. 

Bork JT, Heil EL, Berry S, Lopes E, Dave R, Gilliam BL, Amoroso A. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections. Infect Dis Ther. 2019, 8(2): 171-184.

Bork JT, Claeys K, Heil E, Banoub M, Leekha S, Sorkin J, Kleinberg M. The Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight: A propensity-score matched study. Antimicrob Agents Chemoth 2020, 64(8).

Hauser N, Kim JJ, Leuthy PM, Schmalzle SA, Bork JT. Multicenter retrospective cohort study of the clinical significance of Staphylococcus lugdunensis isolated from a single blood culture set. Diag Micro Infect Dis 2020.

Bork JT, Leekha S, Claeys K, Seung H, Tripoli M, Amoroso A, Heil EL. Change in Hospital Antibiotic Use and Acquisition of Multidrug Resistant Gram-Negative Organisms After the Onset of Coronavirus Disease 2019. Infect Control Hosp Epid 2020.